August 12, 2008Hypertension
Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early Atherosclerosis
Why the study?
Does atrasentan improve hemodynamic and metabolic responses in patients with cardiovascular risk and early atherosclerosis?
Population
72 patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary…
Comparison
Atrasentan for 6 months vs Placebo
Design
RCT, randomly assigned, double-blind
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Supports atrasentan for aortic BP reduction in CV risk; extends endothelin antagonism to early atherosclerosis.
Structured PICO
Does atrasentan improve hemodynamic and metabolic responses in patients with cardiovascular risk and early atherosclerosis?
P
Population
72 patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary angiogram
I
Intervention
Atrasentan for 6 months
C
Comparator
Placebo
O
Outcome
Safety and hemodynamic and metabolic responses at 6 monthssurrogate
Six months of atrasentan treatment significantly reduced blood pressure and improved glucose and lipid metabolism in patients with cardiovascular risk and nonobstructive coronary artery disease.
Cite This Study
Raichlin et al. (2008) studied this question.